In my last official address to the CPDD membership as President, I will reflect a little bit on the past, but mostly want to highlight the prospects and opportunities for the future of the College and for drug and alcohol abuse/dependence prevention, research and treatment. First, it has certainly been a “lively” year and to be honest, I had not fully appreciated the complexities of running a scientific organization and the breadth of issues that come up on a nearly daily basis. Our Executive Office handles so many different issues that it is a challenge to keep up with it sometimes. However, Marty, Ellen and the rest of their team provide so much infrastructure support that being President was not only quite manageable (along with all of my other duties at McLean Hospital), but actually quite an enjoyable experience that I will truly miss. Marty’s one-score-and-six years of service as our Executive Officer have helped propel the College to its current level of respect and esteem among other organizations and the NIH. Ellen’s knowledge of nearly every voxel of this organization is staggering and her rapid, thoughtful and cheery response to my occasional inane questions was most appreciated. In fact, I may need substitution therapy as I go through withdrawal from my nearly daily e-mails with Ellen! The year did go by rather quickly and sometimes I feel as though I am just getting the hang of this—and it is almost over.

Having Anna Rose Childress as Past-President for continuity-based guidance was invaluable and I am convinced that the College’s model of a “three-year” program for the President [President-Elect, President and Past-President] is a solid concept that ensures consistent leadership and is not unlike that old idiom that we are taught in school: “watch one, do one, teach one”. She certainly made it much easier to be President and I thank her for that. Richard De La Garza will be taking over as President at the end of this coming Annual Meeting and he has been steadily assuming more and more responsibilities as he prepares to take the leadership role—we will be in good hands. To Frank Vocci, our incoming President-Elect, I say, “it’s still not too late to RUN!” Only kidding Frank, I know that your years at NIDA Medication Development have prepared you well for this role and the College will certainly benefit from your extensive experience at a time where we will be redefining ourselves. Ted Cicero has been instrumental in helping to guide us along the path of continued fiscal solvency and I look forward to his continued sage advice. Finally, I have enjoyed a renewed relationship (from my NIDA-K days) with one of the true giants in our field—Bill Dewey. I remain in awe of his energy, statesmanship, knowledge of pharmacology, political awareness and the ability to identify the most important points of any issue and remain focused on them. I dare say that a good deal of my scientific and political opinions were shaped by my many
President’s Column continued from page 1

Now for the future... There are both short- and long-term plans that must be considered by any organization—and ours is no exception. As for the long-term stability of the College, I am happy to report that we have secured a plan that will allow the Executive Office to remain at Temple, where we have enjoyed so many benefits for so many years. More details will be forthcoming at the Plenary Session in June, but suffice it to say we were told by the administration, “it has been an honor to have CPDD located at Temple and we see no reason to change that.” Thus, we will retain the solid foundation for the College even when Marty Adler retires. He thinks it will be soon, but I got a look at the fine print of his contract and he is not even eligible for retirement until he is 112 years old! More seriously, the day-to-day operations of the College will be steered by the steady hand of Ellen Geller and her team—thus ensuring a nearly invisible transition to the next decades of CPDD’s future.

Our journal, Drug and Alcohol Dependence, continues to out-perform many other journals under the strong leadership of Eric Strain. Impact factors, number (and quality) of submissions, review turnaround times, quality of reviews, etc., all continue to improve at a brisk pace. This is a healthy indicator that we are making an impact on the field as we continue to identify gaps in the literature and fill them with new knowledge that will only serve to help those less fortunate than ourselves. Our annual scientific program, which is a snapshot of ongoing research that our members and colleagues are conducting, continues to impress me as CPDD continues to be viewed as the place to bring one’s high quality and cutting-edge research. Thanks are due to Sandra Comer and her Program Committee for ensuring that the high standards are met each year. I would like to take a moment to clear up one misconception about the “titles” of the sessions. As much as I would love to take credit for the really creative ones over the past few years, I have not made one up since leaving the Program Committee in 2004.

The future of NIDA and NIAAA is, I am sure, on everyone’s minds. The proposal to dissolve these two Institutes and create a new one with the tentative title of National Institute on Substance Use and Addictive Disorders or NISUAD has had a long and arduous path and while the final decision on whether the new Institute will be formed has yet to be made, processes have been set in motion by the NIH such that well-crafted, scientifically sound and evidence-based responses from the scientific community have been solicited—I hope that you answered this call and sent your thoughts by May 11th. Obviously, Congress will need to approve any appropriations to create this Institute, but the distribution of resources and the profile of the research portfolio are clearly going to be promulgated by NIH.

If you had a chance to listen in on the NIH Webinar on April 2nd from 3-4 pm, you would have heard some of the questions that Marty Adler, Bill Dewey and I posed. Fundamentally, the strategic planning is focused on deciding in which Institute certain research directives should belong. Thus, some research could be moved out of NIDA and NIAAA into other institutes while other research in non-drug/alcohol abuse institutes might be moved into this new Institute on Addictive Disorders. The answers to our, as well as many other, questions suggests that the funding of this (as well as the other affected institutes), will follow the portfolio. If the overall NIH budget remains stable, then the funding of research projects should remain constant and it is a matter of relocating the grants management of these projects. However,
as you well know, should projects be moved into a different institute where the long-term strategic plans do not include such ventures, then they could fail to thrive. In addition, we all have spent a good deal of time working with our Program Officers and should our grants be moved, we will need to re-establish these relationships. So, the strategic planning of where funded research sits within the NIH foundation is actually a very important issue. Of course, level of NIH funding is always a concern and should it dip further, then the future of certain research directives will be in jeopardy. We hope to minimize that by ensuring that key and important research directives continue to receive the attention they deserve.

Since this process first started under Anna Rose’s term as President, we have remained steady in our position of offering CPDD’s vast array of knowledge and skill in this area to NIH as well as to Nora Volkow and her staff as it unfolds. To this end, the CPDD Executive Committee composed a detailed response to this RFI that we posted on the CPDD website for all members to view; I hope that you have taken some time to review it. We spent a good deal of time talking with many individuals as we developed this document. It was not designed to be comprehensive as there just is no easy way to compress the breadth and depth of the research prowess of the CPDD membership in a few pages of text. We know that some areas of research were not included in this letter, but we had to strike a healthy balance between full comprehensive portfolio construction and making key statements about the plan. As such, we chose to focus on the more controversial and thematic aspects of CPDD's interests. I know that many of you answered the call and filled in some of the gaps.

Well, there it is—a year’s worth of activities compressed into three short columns. It has been an honor to serve in this capacity and to have the opportunity to participate in defining the vision and supporting the mission of the College. I am pleased to say that the S.S. CPDD is a solid vessel with many oars in place, and from my perspective, they are all in the water! It is indeed both an exciting and an anxiety-provoking time, but I am convinced that by following a path that promotes excellence, eschews obfuscation, and supports the careers of the next generation of addiction scientists, we will weather this era of uncertain directives and funding. I look forward to seeing all of you in Palm Springs next month.

---

2012 Meeting of the International Study Group Investigating Drugs As Reinforcers (ISGIDAR)

8:30 a.m. - 5:00 p.m. Saturday, June 9, 2012
La Quinta, Palm Springs, CA

Breakfast & Registration ($80) at the door at 8:30; talks at 9:00 a.m.
Lunch complimentary with prior reservation
(pre-payment not necessary but lunch reservation necessary,
contact wjl6w@eservices.virgina.edu
For further information, contact Bill Fantegrossi, WEFantegrossi@uams.edu

Congratulations!

Frank Voci, Ph.D. is our new President-Elect
Linda Dwoskin, Ph.D.
Steve Higgins, Ph.D.
Carl Hart, Ph.D.
and Greg Miller, Ph.D. will join the Board of Directors.
New and Emerging Psychoactive Substances: Second Interdisciplinary Forum

Join the U.S. National Institute on Drug Abuse (NIDA) International Program and its 2012 partner, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), for the 2012 NIDA International Forum, which builds on the 2011 EMCDDA First International Multidisciplinary Forum on New Drugs. The 2012 NIDA International Forum will focus on new and emerging synthetic and natural drugs, such as synthetic cannabinoid receptor agonists (e.g., Spice) and stimulants (e.g., cathinones).

The research symposium, poster session, and network-building activities focus on the range and quality of drug abuse research conducted around the world. Participants meet talented colleagues and learn about drug abuse research and policy issues in other countries as well as the NIDA-supported fellowships and other programs that can support international collaborations.

Highlights

Friday, June 8, 2012
• Workshop: Community Epidemiology Work Group and Network-Based Models for Monitoring Drug Abuse Trends
• NIDA International Fellowship Programs Alumni Meeting
• Opportunities For International Collaboration in Genetics and Drug Abuse Research
• An Open Access Research Guide to Drug and Alcohol Studies: Supporting Information Needs in Developing Nations
• ISAJE Writing Mentor Program
• Fellowship Recruitment Discussion

Saturday, June 9, 2012
• Plenary Session
• International Research Reports
• New and Emerging Psychoactive Substance: Global Updates
• New and Emerging Psychoactive Substances: Implications for Prevention and Treatment
• Drugged Driving: Patterns, Impairment, and Policy Responses

Monday, June, 11, 2012
• Poster Session

Meeting programs and other information is also available at http://www.cvent.com/events/2012-nida-international-forum/event-summary-993dab44351348b1874d61aba460c8e5.aspx
Meeting Highlights – The 2011 Mentorship Award

This award is given yearly to a member of CPDD who has been an exemplary mentor to developing researchers in the field of drug dependence.

2011 Awardee:
Stephen G. Holtzman, Ph.D.

Stephen G. Holtzman received a Ph.D. in pharmacology from the University of Michigan in 1969, the year after he gave his first research report at a CPDD meeting. Since then he was at Emory University, where he rose through the faculty ranks from Instructor to Professor of Pharmacology, School of Medicine, and Collaborative Scientist, Yerkes Regional Primate Research Center. He had a long-standing interest in the behavioral pharmacology of abused drugs, especially opioids and psychomotor stimulants. He served several terms on NIDA study sections and was a member of the NIDA Training and Career Development Review Committee. He was active in several scientific organizations, such as the American Society for Pharmacology and Experimental Therapeutics (ASPET) where he was chairman of the Division for Neuropharmacology and also served as president. He was also on the editorial board of several journals. He served CODD as Chair of the Credentials Committee, as a member of the Publications, Awards, and Drug Evaluation Committees (among others), as president, and two terms as treasurer. He was P.I of many grants throughout his entire career. From graduate school days until his retirement in 2007 he had 42 years of continuous NIH funding, including a MERIT award from NIDA, Scientist Development awards, Scientist awards, and Senior Scientist awards. He was selected Outstanding Alumnus of the Department of Pharmacology at the University of Michigan in 1999. He authored around 400 publications with 250 full manuscripts. His lab produced 17 Ph.D.s and one master’s degree. He had 21 postdoctoral trainees.

Introductory remarks by Heather Kimmel, Ph.D.

It is with great pleasure that I present the CPDD Mentorship Award to Yung-Fong Song and Adrian on behalf of Steve Holtzman, who passed away in April of this year. I wish he could be here with us today, as so many of his former trainees are here to honor him. It seems very appropriate to be doing this today, on Father’s Day, as he was a father figure to so many of us.

Born in Brooklyn, NY, Steve Holtzman received his B.S. in pharmacy from Columbia University and his Ph.D. in pharmacology from the University of Michigan, where he studied in the laboratory of Julian Villarreal. In 1969, Steve joined the Department of Pharmacology at Emory University as a postdoctoral fellow and spent the rest of his career at Emory until retiring in 2007. One of Steve’s lasting scientific achievements is the principal role he played in the development and validation of behavioral drug discrimination in the characterization of CNS-acting drugs. Much of Steve’s research concentrated on the consequences of chronic administration of opioids and psychomotor stimulants like caffeine. He also had a remarkable 42-year record of continuous NIH funding!

In addition to his laboratory research, Steve was also actively engaged in service to the pharmacology community through CPDD, ASPET, JPET, and many other organizations. With regard to CPDD, he served as a

Continued on page 6
member of the Board of Directors from 1992 to 2009 and was elected President in 1997. He also served as CPDD Treasurer from 1998-2004. During his long career, he trained 17 PhD graduate students and mentored 21 postdoctoral fellows as well as countless junior faculty members.

These facts and figures do not communicate what a truly great mentor Steve was. He approached every one of us as intelligent individuals, ready to learn, regardless of our diverse backgrounds or prior academic performances. Even when something wasn’t clear to us right away, Steve would always take the time to patiently explain concepts and give examples, usually resulting in the “aha!” moment for us and a “you got it!” from him. He allowed each and every one of us to think for ourselves and to try out our own ideas. He listened to us talk: patiently waiting through our stumbles, reverses, and long-winded explanations. Then he’d reflect back our ideas in clear, crisp language, and take it to the next step. What is astonishing is that all of us had this particular experience with him, and we felt that he really enjoyed his students. As Kahlil Gibran said, “The teacher who is indeed wise does not bid you to enter the house of his wisdom but rather leads you to the threshold of your mind.”

Steve was always direct and honest. You knew exactly what he thought of what you had to say, by the position of his eyebrows. Neutral or straight was good. Up meant that you surprised him. Down meant that you were wrong, just wrong. Dancing eyebrows meant he was excited! Steve was well-known for his dry wit - so dry that he often had to tell his hapless students that it was okay to laugh. He always appreciated a good story and would listen to this with the same intensity as if we were discussing a journal club paper.

Steve supported us all while we were in his laboratory, but also after we went on to other phases of our careers. He never expected that we would all follow in his footsteps and have academic research careers. He let us know that he wanted us to be happy in our career choices and that he was proud of us regardless of what those choices were.

He expected much from each of us, but he also recognized that we were individuals with lives apart from the lab. Too many of us endured various hardships and tragedies while we were working with him, but he supported us all with his calm words and compassion. In that way, he taught us to be good people who also happened to be good scientists. He fostered a sense of loyalty to him and to the “Holtzman” family of mentees that is rarely seen. We have all tried to follow his example of thoughtfulness, patience, conviction, steadfastness, and humor, and to pass his legacy on to our own trainees.

He was a great scientist and an even greater man, and we are all proud to be a part of his legacy. Recently, Jim O’Callaghan, Steve’s first PhD student, told me “no one could have asked for more support, more time spent, more fantastic guidance and the best training any student could ever ask for...a graduate training experience that forever affects your career progress and enjoyment of research.” All of us who had the privilege of training with Steve agree and we thank the CPDD awards selection committee for honoring him in this way.
The International Women's and Children's Health and Gender Group
Fifth Meeting and Conference
Friday, June 8, 2012, 11:00 to 18:00
Palm Springs, California, USA

Women, Substance Abuse, Context & Treatment: Global Issues

This conference will bring together expert researchers and clinical providers passionate about and committed to improving the lives of women and children.

CO-CHAIRS
Frances E. Ashe-Goins, Office on Women's Health, U.S. Department of Health and Human Services
Wendee Wechsberg, Substance Abuse Treatment Evaluation and Interventions, RTI International

PLENARY LUNCH SPEAKER
Cora Lee Wetherington, Women and Sex/Gender Differences, Research Coordinator, NIDA – Sex/Gender Differences in Drug Abuse & Implications for Gender-Focused Treatment

SPEAKERS
Trecia Wouldes, The early environments of children born to mothers who use methamphetamine: A comparison of two cultures
Irma Kirtadze, A formative study of drug-using women in Georgia: Setting the stage for an RCT
Olga Tousova, HIV risks among women IDUs and bridging populations in St. Petersburg, Russia

SPECIAL EVENTS
Thema Bryant Davis, Poetess on and about women

DISCUSSION TABLES WITH EXPERTS Your choice of two 45-minute sessions.
1. Evidence-based women-centered treatment
2. Women and co-occurring disorders
3. Family issues: Infant attachment, childhood trauma
4. Global issues related to health disparities
5. Evidence-based, young women-focused preventions
6. Perinatal substance abuse
7. What structural interventions are working for women
8. Gender-based, interpersonal violence and victimization

Registration is $50 US ($25 for attendees from developing countries)
Lunch is included. To register go to:
For more information, contact Dr. Wendee Wechsberg, wmw@rti.org.
Meeting Highlights – The 2011 J. Michael Morrison Award

As a memorial to this well-liked and respected administrator at NIDA, an award is given every other year for outstanding contributions in the area of scientific administration related to drugs of abuse.

2011 Awardee:
Steven W. Gust, Ph.D.

Steven W. Gust, Ph.D. has worked at NIDA since 1986. Since 1999, he has been Director of the NIDA International Program, leading the Institute’s efforts to support international research and training through innovative and effective programs such as the INVEST and Humphrey fellowships, which support year-long research and educational experiences for qualified international investigators. For the last 12 years, Dr. Gust also has organized an international satellite to the CPDD conference that has grown impressively and now brings over 250 international scientists to CPDD every year. Before assuming leadership of the NIDA International Program, Dr. Gust served as deputy and acting director of the Institute’s Office on AIDS, chief of the Division of Applied Research Workplace Performance Research Branch, and program manager in the Clinical and Behavioral Pharmacology Branch Division of Clinical Research. In 1993, Dr. Gust received a prestigious appointment as a congressional fellow, where he worked with the U.S. Senate Labor and Human Resources Committee and the late Senator Paul Wellstone (D-Minnesota). He has served on the Surgeons General’s Advisory Group on the Health Effects of Smokeless Tobacco; the Transportation Research Board Committee on Alcohol, Other Drugs, and Transportation; and the White House Health Care Reform Task Force.

Introduction by
Robert Balster, Ph.D.

All of you attending CPDD know that there is an increasing awareness that drug abuse is a global problem and that ultimate solutions require an international vision. It is in this context that we honor today Dr. Steven Gust with the J. Michael Morrison Award for outstanding contributions in the area of scientific administration related to drug abuse. For 25 years, Dr. Gust has been an exemplary science administrator at NIDA. This award is primarily in recognition of his service since 1999 as Director of The International Program. The International Program at NIDA is a crown jewel in the global health efforts of NIH and one of the most vibrant and successful programs at the Institute. Under the leadership of Dr. Gust, the NIDA International Program has fostered excellence in both research and training opportunities and in building international cooperation in addiction science. Attendees at CPDD know that NIDA sponsors a very successful International Forum leading up to our meeting, and we invite all of you to attend the international poster session on Monday evening to capture some of the excitement of NIDA’s international efforts. The NIDA International Forum has been growing every year and now regularly attracts about 100 attendees from around the world, many of whom remain for the CPDD meeting and become involved in the activities of the College. In addition, Dr. Gust has been a leader in recognizing the potential of the Internet to deliver relatively low-cost international communications, research training, and education programs, supporting the development of many innovative tools for online collaboration. Prior to directing NIDA’s International Program, Dr. Gust also served in several capacities to advance the important HIV/AIDS efforts at NIDA, where he brought national and international attention to the behavioral connections between drug use and AIDS, highlighting

Continued on page 9
the critical links between risky behaviors and HIV infection. Dr. Gust is the model of an effective science administrator, a good listener, a leader by consensus, and someone who inspires trust and commitment. Through this award, the College also wants to recognize the work of NIDA’s entire International Office staff and contractors who together with Dr. Gust have made this program such a success. Through his roles at NIDA, Dr. Gust has significantly influenced global scientific cooperation on drug abuse and drug-related HIV/AIDS and for this we are pleased to ask him to accept the 2011 Morrison Award.

Acceptance Remarks by Dr. Gust

It is hard to express how honored I feel to be nominated for and to receive CPDD’s J. Michael Morrison Award. It is both exciting and very humbling. I’d like to thank Marilyn Carroll and Nancy Mello for all their efforts in nominating me and Marilyn for her very kind and generous, if somewhat over-the-top, introduction. And I thank the members of the CPDD Awards Committee for selecting me.

An award like this often involves the commitment, dedication and hard work of lots of people, and that is certainly true in this case. There are many people who have helped, supported and encouraged me, and without them I would not be receiving this award. This includes many of you in this audience as well as colleagues back at NIDA, and I thank you all.

CPDD Conference – Special Events

We have a dynamite line-up in store for you this year! There will be about 150 short talks to hear and 600 posters to see. In addition to the symposia and workshops that are listed on the Web, the topic of the President’s Symposium will be Addressing the Challenges of Tobacco and Alcohol Use – Presentations and Open Forum. It will take place on Sunday, June 10, 2012, 1:15-2:30. For the Sunday morning opening session, we will have a report from Nora Volkow, Director of NIDA, and another from Gil Kerlikowske, Director of ONDCP, on National Drug Control Policy: Emerging Opportunities for Policy and Biomedical Research. The Eddy Award Lecture will be presented by this year’s recipient of the award, Ed Sellers. On Monday morning, the Marian W. Fischman Award Lecture will be given by this year’s awardee, Marilyn Carroll. There will be several forums on specific issues including Animals in Research, Academia/Industry/Government Relations, Public Policy and Media Training. The Brunch with Champions on June 14, 12:00-1:30 will provide an opportunity for predocs, postdocs, and junior faculty to chat informally with senior investigators and scientific administrators. You must pre-register and attendance will be limited. For movie night, we will be screening 28 Days starring Sandra Bullock, a film about alcohol addiction and rehab, complete with popcorn & lemonade. Plan to stay through Thursday so that you can participate in our Sweepstakes Drawing for some exciting prizes like free membership dues, and free hotel nights and meeting registration for 2013 (San Diego!)

Also, CME credit through Temple University School of Medicine is available for selected symposia & workshops. Registration for CME credits is $75. The fee includes 1-20 credits maximum.

-- Contributed by Ellen Geller
Palm Springs Travel Tips

As you make your travel plans, please keep in mind that there are alternatives to flying into Palm Springs airport. Although it is the closest to La Quinta, flights in the summer are limited and there are few non-stops.

Also, there is no regularly scheduled shuttle service from the airport, although you can arrange for a pick up in advance. Airport transportation is available through "At your Service" (1-888-700-7888) for $46 (plus gratuity) per person one way, $30 per person for two, or $25 per person for three. A taxi would be $65 - $75 each way. Reservations must be made 3 days or more in advance. If you book your flight through Sailair/Frosch, they can try to arrange transportation with others arriving at the same time through Desert Valley Shuttle or another service.

If you are traveling alone, it is more economical to rent a car at the airport for $35 (see our link for Enterprise on the Web at: http://www.cpdd.vcu.edu/Pages/2012CarRentalPalmSpringsInfo.pdf) that you can drop at the hotel. You can rent one for the same price for the return trip. The drive is about 30 minutes and can be done without going on the highway.

Alternatively, you can fly into one of the other nearby airports and rent a car. Ontario is the best, in terms of distance (64 miles) and the drive. San Diego is 85 miles away; Orange County and LAX are each 117 miles from Palm Springs. It is not a bad idea to have a car if you want to explore the area.

Joshua Tree National Park is less than an hour away. This desert park is home to numerous varieties of plants and animals that brave the climatic extremes and unpredictable rain. With almost 800,000 acres of land and three ecosystems surviving within it, you just might catch a glimpse of a California Mountain Lion stalking its prey or a California Desert Bat flying overhead. A trip to the top of Mt. San Jacinto (8,516 feet) on the Palm Springs Aerial Tramway is an awesome experience in the world’s largest single span vertical rotating cable car. Other attractions are the Coachella Valley Preserve, Moorten’s Botanical Garden and The Living Desert, which showcase the unique desert flora and fauna. (The last is less than 20 minutes by car from the hotel and not to be missed!)

For the golfers among us, La Quinta, California, is home to some of the most phenomenal golf communities in the world. In fact, it has been named “America’s ultimate golfing destination”. There’s golfing at the City’s spectacular public course, SilverRock Resort; dining and shopping in the quaint Village area or along the Highway 111 commercial corridor; biking along the Bear Creek Trail; and hiking in the Santa Rosa and San Jacinto mountains.

The weather should be very warm but very dry--it’s the desert! Remember to drink lots of water and enjoy the outside during the cooler parts of the day. We have planned the meeting so that you can stay inside for lunch at the posters most days and have some early mornings free. We hope that you will find both the scientific program and the Palm Springs area interesting and enjoyable.

-- Contributed by Ellen Geller
SAMHSA PRE-CONFERENCE SESSION
Exploring the Dimensions of Recovery and Recovery Support Services

Saturday, June 9, 2012
8:30 AM – 5:15 PM

Addresses:
- Keynote address:
  --Richard Kopanda M.A., Deputy Director CSAT/SAMHSA
- Plenary Address:
  --Redonna K. Chandler, Ph.D.
- Recovery Across the Life Span: Resiliency, Wellness, and Family
  --Dennis D. Embry, Ph.D.
- Accreditation Standards for Recovery Community Organizations
  --Tom Hill, M.S.W.

Symposia:
- Research on Best Practices in Recovery Support
- Peer Recovery Community Organizations and the Role of Peers
- Recovery Support Services: Housing, Employment, and Civic Restoration
- Financing Recovery Support Services

Round Table Session: Trauma Issues with Specific Populations
- How would peer recovery support services fit into your agency or services?

CEUs will be available. Please contact JBS International, Inc. (JBS) Staff:
Peter Edwards
JBS International, Inc.
Phone: (240) 645-4130
Email: pedwards@jbsinternational.com or samhsatraining@jbsinternational.com

For further information:

or contact:
Tyauna Brown, CMP or Verna Robinson, CMP, CGMP
Synergy Enterprises, Inc.
Phone: (240) 485–1700, Ext. 3618 Phone: (240) 485–1700, Ext. 3639
E-mail: tbrown@seiservices.com E-mail:vrobinson@seiservices.com

CPDD membership includes a subscription to Drug and Alcohol Dependence, which is ranked among the most cited substance abuse research journals.
Meeting Highlights – The 2011 CPDD/NIDA Media Award

This award is given to a member of the media who has made major contributions to the public understanding of scientific issues concerning drug use disorders.

2011 Awardee: Justin Hunt

Justin Hunt is a former broadcast journalist who spent eight years working with NBC affiliates before becoming the award-winning director of the feature length documentaries “Absent” and “American Meth.” Combined, the films have won over a dozen film festivals around the world, including the Cinema City Int’l film Festival at Universal Studios and the Marbella Int’l Film Festival in Spain. In early 2007, “American Meth” was release on DVD and became one of the most rented documentaries of that year. Since then, the film has grown in popularity, and is currently available in over 50 million households through Cox, Comcast and Time Warner cable networks. It is also featured on Netflix and this summer will become the first independent documentary to be featured on Amazon.com’s Instant Video landing page. American Meth has also enjoyed successful runs via both inDEMAND and ONDEMAND, making it available to nearly 50 million cable households. In the fall of 2008, Justin was sent to Washington, D.C., by Governor Bill Richardson to represent New Mexico at a national meth conference. In 2011, Justin appeared on the Fox national morning program, “Fox & Friends”, along with his friend James Hetfield, co-founder of the band Metallica, to discuss his latest film, “Absent”, which deals with the impact of disengaged fathers. Justin lives in Gilbert, Arizona, with his 1-year-old son, Lantz, and 8-year-old daughter, Abbey.

Introduction by Marc Kaufman, Ph.D.

On behalf of the CPDD Media Relations Committee, I’m very pleased to be here this morning to participate in this joint presentation of the 2011 Media Award by CPDD and NIDA, to Mr. Justin Hunt, award-winning producer of the film American Meth.

American Meth graphically portrays the struggles faced by a number of families and individuals afflicted by methamphetamine abuse, providing a snapshot of some of the significant societal burdens associated with methamphetamine. Mr. Hunt lived with one of the families portrayed in the film during filming and captured in great detail the devastation that the drug can cause to families.

The film has won several awards including Best Documentary at the Silk City Flick Fest (2010), Best Documentary at the Cinema City International and TriMedia Film Festivals (2007), and the Most Socially Engaging Film at the Eugene International Film Festival (2007).

The 72-minute film will be shown on Wednesday evening as part of Film Night. If you are not able to watch it then, it is available for streaming on Hulu.

An interesting and informative website including public health resources available for those afflicted with methamphetamine abuse is associated with the film at the URL americanmethmovie.com, making the film a truly multimedia experience.

By winning this award, Mr. Hunt will receive a cash prize and an inscribed award plaque. Please join me in extending a warm welcome and congratulations to Mr. Justin Hunt.

Media Award acceptance remarks:

Happy Father's Day. When Marc asked me to comment on what I learned from making the film, my initial thoughts were, obviously, the utterly devastating nature of this drug, the process of telling the story, the people I’d met along the way, maybe even the hurdles that had to be cleared to complete an independent documentary. Better yet, perhaps I could...
Biomarker Development for Substance-Use Disorders  
Saturday, June 9, 2012 – 8:00AM - 5:00PM

**Chairs:**
- Gerry Moeller, MD – University of Texas – Houston
- Shashi Amur, PhD – US Food & Drug Administration

**Abstract:**
Whereas maintained abstinence from substance abuse represents the ideal primary outcome, one of the major impediments to efficient medications development is the lack of alternative biomarkers that can be used to quantify objectively harm reduction and/or the longitudinal recovery from SUDs. The goals for this meeting are to identify, prioritize and standardize possible biomarkers that could be used to characterize more objectively cocaine-dependence and enhance the efficiency by which clinical drug-development trials progress. (Borsook D, Hargreaves RJ, Becerra L. Expert Opin Drug Discov. 2011; 6(6): 597-617.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 8:20 AM</td>
<td><strong>Introduction</strong></td>
<td><strong>Kristopher Bough, PhD</strong>, National Institute on Drug Abuse</td>
<td></td>
</tr>
<tr>
<td>8:20 – 8:50 AM</td>
<td><strong>CARDIOVASCULAR</strong></td>
<td><strong>Kyle Kampman, MD</strong>, University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>8:50 – 9:20 AM</td>
<td></td>
<td><strong>Joy Schmitz, PhD</strong>, University of Texas at Houston</td>
<td></td>
</tr>
<tr>
<td>9:20 – 9:50 AM</td>
<td></td>
<td><strong>Anne Dougherty, MD</strong>, University of Texas at Houston</td>
<td></td>
</tr>
<tr>
<td>9:50 – 10:20 AM</td>
<td></td>
<td><strong>Shenghan Lai, MD</strong>, Johns Hopkins University</td>
<td></td>
</tr>
<tr>
<td>10:20 – 10:40 AM</td>
<td></td>
<td><strong>Guifang Lao, MD, PhD</strong>, (NIDA) Discussion Chair</td>
<td></td>
</tr>
<tr>
<td>10:55 – 11:25 AM</td>
<td><strong>NEUROIMAGING</strong></td>
<td><strong>Gerry Moeller, MD</strong>, UT at Houston</td>
<td></td>
</tr>
<tr>
<td>11:25 – 11:55 AM</td>
<td></td>
<td><strong>Diana Martinez, MD</strong>, Columbia University</td>
<td></td>
</tr>
<tr>
<td>11:55 – 12:15 PM</td>
<td></td>
<td><strong>Jim Bjork, PhD</strong>, (NIDA) Discussion Chair</td>
<td></td>
</tr>
<tr>
<td>12:15 – 1:45 PM</td>
<td><strong>Lunch</strong></td>
<td><strong>Lunch (on your own)</strong></td>
<td></td>
</tr>
<tr>
<td>1:45 – 2:15 PM</td>
<td><strong>BIOCHEMICAL / TRANSLATIONAL</strong></td>
<td><strong>Scott Hemby, PhD</strong>, Wake Forest University</td>
<td></td>
</tr>
<tr>
<td>2:15 – 2:45 PM</td>
<td></td>
<td><strong>Jeff Buckthal, PhD</strong>, Metabolon, Inc.</td>
<td></td>
</tr>
<tr>
<td>2:45 – 3:15 PM</td>
<td></td>
<td><strong>Kalpana Merchant, PhD</strong>, CSO Translational Science, Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>3:15 – 3:45 PM</td>
<td></td>
<td><strong>Charles Green, Ph.D.,</strong> University of Texas at Houston</td>
<td></td>
</tr>
<tr>
<td>4:00 – 4:30 PM</td>
<td><strong>REGULATORY</strong></td>
<td><strong>Shashi Amur, PhD</strong>, Biomarker Qualification Science Coordinator, FDA</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Final Wrap-Up (panel discussion)</strong></td>
<td><strong>Drs. Shashi Amur, Kristopher Bough, and Gerry Moeller</strong></td>
<td></td>
</tr>
</tbody>
</table>

For more information about the Friends of NIDA, visit their website at www.thefriendsofnida.org
**Contingency Management Working Group**

The Contingency Management (CM) Working Group is a night workshop held annually at CPDD that provides an opportunity to learn more about CM applications for behavior change. CM (also referred to as motivational incentives or voucher-based reinforcement therapy) is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and within many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). During this year’s 18th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research and dissemination, with an emphasis on developing or improving research strategies by seeking audience input and providing opportunities for junior and senior researchers to interact. The agenda for speakers will be posted on the CPDD listserv prior to the conference. The workshop is open to all conference attendees, and anyone who is using CM to promote behavior change, has an interest in learning more about CM or would like to become acquainted with other researchers conducting CM is particularly encouraged to attend. The CM Working Group will be held on Monday June 11th from 8:00 – 10:00 in Flores 6-8 and the agenda will be mailed to the CPDD listserv prior to the conference. Hope to see you there!

-- Contributed by Kelly Dunn, Ph.D.

Media Award continued from page 12

discuss how my external observation of this drug may mesh with the internal science that is so heavily researched by those of you in that field. But as I began to establish perspective on the significance of this prestigious award, the amount of people involved in this battle against substance abuse, and the effort output as a result of that battle, my thoughts shifted.

They shifted from WHAT I've done, to WHY. At the core, for me, it is because of belief and faith. The belief that I'm doing what I've been called to do and faith in the fact that that particular skill set was given to me for a reason. That is what I feel we all have in common here this morning.

I am simply a filmmaker. I've attempted to make a difference in this battle, using the weapons that "I" wield, through the project that I'm being honored for here this morning. But as I scanned through the seemingly innumerable sessions on the effects of pre-natal cocaine usage and the abuse of over-the-counter codeine in Australia, as I sit and visit about the months and months of research by people like Kunal Ghandi, as I begin to understand the diligence put forth by the professionals that fill this room...it is I who wish to honor you. And to encourage each of you to continue, with vigor, the forceful advancement of progress, and remember, often, not WHAT it is your doing, but WHY.

Proverbs reads "see a person diligent in their work? They shall stand before kings". Although the work we do may not place us before kings, our efforts do have the potential to change the kingdom.

Thank you for this amazing honor, and I hope you all have a wonderful conference.